NEW YORK (Reuters Health)—In patients with active non-radiographic axial spondyloarthritis (nr-axSpA) who achieved remission while taking adalimumab, researchers saw fewer flares among those who continued taking the drug than among those who stopped taking it. “The results showed that continued therapy with adalimumab was associated with a higher rate of maintenance of remission compared with…